- ABA Groups
- Resources for Lawyers
- Career Center
- About Us
The year 2014 is expected to bring major changes to the 340B Drug Discount Program. To understand where the Program is going, it helps to know where it has been. What is the 340B Drug Program and Why Does it Exist?
The Final Omnibus Rule implementing revisions to the Health Insurance Portability and Accountability Act (“HIPAA”) has been in effect for over one year now. While providers have had time to digest the changes brought about by the Final Omnibus Rule, certain provisions continue to cause difficulties from a practical perspective.
On January 23, 2014, the Washington State Supreme Court (“Court”) decided a case with significant implications for Washington healthcare providers that employ physicians (or other healthcare practitioners) and the attorneys who represent those organizations.
The Health Insurance Portability and Accountability Act’s Security Rule sets forth standards, implementation specifications, and requirements for the security of electronic protected health information (“ePHI”) by covered entities and business associates. Perhaps one of the most confounding required implementation specifications within the Security Rule is the risk analysis. o
On February 18, 2014, manufacturers and group purchasing organizations in the life sciences industry could begin to report to the Centers for Medicare & Medicaid Services (“CMS”) payments or other transfers of value to physicians and/or academic medical centers (“AMCs”).